Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Sep;10(5):e163.
doi: 10.1002/ctm2.163.

Tofacitinib treatment alters mucosal immunity and gut microbiota during experimental arthritis

Julie Hablot  1 , Maroua Ferhat  1 , Aonghus Lavelle  2   3   4   5 , Fatouma Salem  1 , Mahdia Taieb  1 , Jasna Medvedovic  6   7 , Nadège Kindt  1 , Pascal Reboul  1 , Frédéric Cailotto  1 , Jean-Yves Jouzeau  1   8 , Gérard Eberl  6   7 , Harry Sokol  2   3   4   5 , David Moulin  1   9
Affiliations

Tofacitinib treatment alters mucosal immunity and gut microbiota during experimental arthritis

Julie Hablot et al. Clin Transl Med. 2020 Sep.
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors declared no conflict of interest.

Figures

FIGURE 1
FIGURE 1
A, Heterologous collagen‐induced arthritis (CIA) was induced in 7 weeks old DBA/1J male mice by an intradermal injection (i.d) of type II bovine collagen (2 mg/mL) emulsified in complete Freund's adjuvant at the base of the tail. At day 21, a booster immunization was performed by an intraperitoneal (i.p) injection of type II collagen (1 mg/mL) in incomplete Freund's adjuvant. Tofacitinib was administered daily (20 mg/kg/day) by i.p injection from arthritis onset (from day 15) until necropsy (day 35). Mice were divided into four groups: (1) vehicle‐treated control; (2) tofactinib‐treated control; (3) vehicle‐treated arthritic, and (4) tofactinib‐treated arthritic mice. Data are compiled from eight mice in each group from three independent experiments. B and C, Disease incidence (B) and disease severity (C) were monitored and scored twice a week from arthritis onset until necropsy. Data are expressed as mean ± SEM for each group. Statistical differences between groups were evaluated using log‐rank test for incidence and using Mann‐Whitney U test for arthritis score. D, Th17 cell number in small intestine Lamina propria (siLP, upper panel) and mesenteric lymph nodes (mLN, lower panel) assessed by flow cytometry after tofacitinib treatment in arthritic mice. Data are expressed as mean ± SD for each group. Statistical differences between groups were evaluated using an ANOVA and Fisher's PLSD post hoc test. E, ILC3 cell number in small intestine Lamina propria (siLP, upper panel) and mesenteric lymph nodes (mLN, lower panel) assessed by flow cytometry after tofacitinib treatment in arthritic mice. Data are expressed as mean ± SD for each group. Statistical differences between groups were evaluated using an ANOVA and Fisher's PLSD post hoc test. F, Tofacitinib effects on microbiota. Upper panel, PCoA plots of Bray‐Curtis divergence for the six times. Significance stars refer to PERMANOVA comparing clustering of arthritic mice treated with placebo (NaCl) or treated with tofacitinib. Control mice are included in the plots for reference. Lower panel: barplots of significantly different taxa by Lefse, comparing arthritic mice given placebo (NaCl) and those given tofacitinib at the three later time points (D21, D28, and D35)
See this image and copyright information in PMC

References

    1. van Vollenhoven R, Lee EB, Strengholt S, et al. Evaluation of the short‐, mid‐, and long‐term effects of tofacitinib on lymphocytes in patients with rheumatoid arthritis. Arthritis Rheumatol. 2019;71:685‐695. - PMC - PubMed
    1. Eberl G. A new vision of immunity: homeostasis of the superorganism. Mucosal Immunology. 2010;3 (5):450–460. 10.1038/mi.2010.20. - DOI - PubMed
    1. Scher JU, Littman DR, Abramson SB. Microbiome in inflammatory arthritis and human rheumatic diseases. Arthritis Rheumatol. 2016;68:35‐45. - PMC - PubMed
    1. Scher JU, Abramson SB. The microbiome and rheumatoid arthritis. Nat Rev Rheumatol. 2011;7:569‐578. - PMC - PubMed
    1. Edwards CJ. Commensal gut bacteria and the etiopathogenesis of rheumatoid arthritis. J Rheumatol. 2008;35:1477‐14797. - PubMed

LinkOut - more resources